Get started
Prestige Consumer Healthcare Inc.Prestige Consumer Healthcare Inc.Prestige Consumer Healthcare Inc.

Prestige Consumer Healthcare Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Technicals Forecast

PBH chart

Upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats

Market capitalization
‪3.30 B‬USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
15.93
Basic EPS (TTM)
4.21USD
Net income (FY)
‪209.34 M‬USD
Revenue (FY)
‪1.13 B‬USD
Shares float
‪49.05 M‬
Beta (1Y)
0.46

About Prestige Consumer Healthcare Inc.

Sector
Health Technology
CEO
Ronald M. Lombardi
Headquarters
Tarrytown
Website
prestigebrands.com
Employees (FY)
570
Founded
1996
FIGI
BBG000QM0RZ4
Prestige Consumer Healthcare, Inc. engages in the marketing, sale, and distribution of pharmaceutical drugs and consumer products. It operates through the North American OTC Healthcare and International OTC Healthcare segments. The North American and International OTC Healthcare segments manage the following brands: BC/Goody's, Beano, Boudreaux's Butt Paste, Chloraseptic, Clear Eyes, Compound W, Debrox, DenTek, Dramamine, Efferdent, Fess, Fleet, Gaviscon, Hydralyte, Luden's, Monistat, Nix, Pedia-Lax, and Summer's Eve. The company was founded in 1996 and is headquartered in Tarrytown, NY.

Financials

Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

Ideas

See all ideas 

News

Keep reading

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating

An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Stock brokers

Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of PBH is 64.98 USD — it has decreased by 2.23% in the past 24 hours. Watch Prestige Consumer Healthcare Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NYSE exchange Prestige Consumer Healthcare Inc. stocks are traded under the ticker PBH.
PBH stock has fallen by 7.04% compared to the previous week, the month change is a 5.17% fall, over the last year Prestige Consumer Healthcare Inc. has showed a 10.30% increase.
We've gathered analysts' opinions on Prestige Consumer Healthcare Inc. future price: according to them, PBH price has a max estimate of 81.00 USD and a min estimate of 65.00 USD. Watch PBH chart and read a more detailed Prestige Consumer Healthcare Inc. stock forecast: see what analysts think of Prestige Consumer Healthcare Inc. and suggest that you do with its stocks.
PBH reached its all-time high on Mar 18, 2024 with the price of 75.31 USD, and its all-time low was 3.92 USD and was reached on Mar 12, 2009. View more price dynamics on PBH chart.
See other stocks reaching their highest and lowest prices.
PBH stock is 4.33% volatile and has beta coefficient of 0.46. Track Prestige Consumer Healthcare Inc. stock price on the chart and check out the list of the most volatile stocks — is Prestige Consumer Healthcare Inc. there?
Today Prestige Consumer Healthcare Inc. has the market capitalization of ‪3.23 B‬, it has decreased by 2.43% over the last week.
Yes, you can track Prestige Consumer Healthcare Inc. financials in yearly and quarterly reports right on TradingView.
Prestige Consumer Healthcare Inc. is going to release the next earnings report on Aug 1, 2024. Keep track of upcoming events with our Earnings Calendar.
PBH earnings for the last quarter are 1.02 USD per share, whereas the estimation was 1.14 USD resulting in a −10.45% surprise. The estimated earnings for the next quarter are 0.86 USD per share. See more details about Prestige Consumer Healthcare Inc. earnings.
Prestige Consumer Healthcare Inc. revenue for the last quarter amounts to ‪276.99 M‬ USD despite the estimated figure of ‪287.42 M‬ USD. In the next quarter revenue is expected to reach ‪260.55 M‬ USD.
PBH net income for the last quarter is ‪49.46 M‬ USD, while the quarter before that showed ‪53.05 M‬ USD of net income which accounts for −6.76% change. Track more Prestige Consumer Healthcare Inc. financial stats to get the full picture.
No, PBH doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of May 17, 2024, the company has 570.00 employees. See our rating of the largest employees — is Prestige Consumer Healthcare Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Prestige Consumer Healthcare Inc. EBITDA is ‪375.92 M‬ USD, and current EBITDA margin is 33.15%. See more stats in Prestige Consumer Healthcare Inc. financial statements.
Like other stocks, PBH shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Prestige Consumer Healthcare Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Prestige Consumer Healthcare Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Prestige Consumer Healthcare Inc. stock shows the buy signal. See more of Prestige Consumer Healthcare Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.